Trials / Recruiting
RecruitingNCT06973356
Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
An Exploratory Clinical Study of Anti-CD19/BCMA CAR Gene Vector Injection (LCAR1901) for the Treatment of Relapsed and Refractory Immune Thrombocytopenia
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Anhui Provincial Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of relapsed and refractory immune thrombocytopenia. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis. | Description: A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg）. |
Timeline
- Start date
- 2025-08-16
- Primary completion
- 2029-06-30
- Completion
- 2029-06-30
- First posted
- 2025-05-15
- Last updated
- 2025-08-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06973356. Inclusion in this directory is not an endorsement.